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Asthma is a chronic airway disease characterised by chronic airway inflammation
and periods of bronchoconstriction. Symptoms of asthma are dyspnoea, cough,
chest pain, fatigue etc. The disease has different stages, depending on the severity,
frequency of symptoms, and objective measurements. The pharmacological
treatment of asthma is based on the severity of the disease. Long-acting B2-agonists
formoterol and salmeterol should be considered when symptoms are moderately
persistent and nightly symptoms occur. They provide an excellent bronchodilating
effect, but there are differences between these compounds. In chapter 2, the state of
the art of the current knowledge of the long-acting 0z agonists is discussed.
Formoterol and salmeterol differ in rate of onset of the bronchodilating effect.
Previously, it was demonstrated that formoterol provided a faster improvement in
lung function (FEV1) than salmeterol after inducing an acute, methacholine-induced
moderate to severe bronchoconstriction. In chapter 3, we demonstrate that
formoterol also provides a rapid subjective improvement of dyspnoea, similar to
that of salbutamol and faster than salmeterol.
A further important difference between formoterol and salmeterol in vitro, is the
full agonistic property (higher intrinsic activity) of formoterol in comparison to the
partial agonist salmeterol. In the subsequent wo chapters (chapters 4 and 5) we
tried to demonstrate this difference in vivo, using methacholine-induced
bronchoconstriction as a model, by studying (chapter 4) the bronchodilating effect
of an additional single dose of salbutamol. The hypothesis was that after
pretreatment with a high dose of salmeterol, the bronchodilating effect of
salbutamol would be decreased, in corttrast o high dose treatment with formoterol.
However, àt the investigated dose of salbutamol, no difference in the
bronchochodilating effect could be demonstrated. In fact, due to the two-week
pretreatment period, the bronchodilating effect of salbutamol was diminished to a
similar extent with both long-actinE lz-a9onists, indicating the development of
tolerance, overshadowing the putative occurrence of antagonistic activity of
salmeterol. Nevertheless, after formoterol pretreatment, a higher dose of
methacholine was needed to induce a similar bronchoconstriction, confirming in
vítro data that formoterol has a greater intrinsic activity than salmeterol.
In chapter 5, a different approach was chosen by studying the acute effects of
salmeterol and formoterol treatment on the bronchodilatory dose response curve of
formoterol, performed on top of a methacholine-induced bronchoconstriction.
Remarkably, also in this study the bronchodilating effects of formoterol were not
differently modulated by pretreatment with salmeterol compared to formoterol.
With the introduction of the long-acting B2-agonists there were two major concerns:
blunting of perception of dyspnoea and decrease of compliance with inhaled
corticosteroids (ICS). As outlined in the introduction of this thesis, the perception of
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dyspnoea is an important feature for the asthmatic patient and a cornerstone in the
treatment of asthma. Using the modified Borg scale, we showed in chapter 6 that a
methacholine-induced moderate to severe bronchoconstriction was well perceived
after two weeks of high dose treatment of long-acting B2-agonists; no differences
were observed between formoterol, salmeterol, and placebo pretreatment. The first
concern appeared therefore to be unjustified. Another concern was that with the
start of the (subjectiveiy) strong-acting long-acting B2-agonists the compliance with
ICS might decrease. ICS do not have an immediate bronchodilating effect and many
patients rate them as ineffective. In chapter 9, we showed that no decrease in
compliance with ICS was observed, when long-acting pz-agonists were added in
patients who chronically use ICS. On the contrary, this sfudy shows that the
addition of long-acting B2-agonists may improve compliance.
Guidelines recommend that long-acting gz-agonists hould always be combined
with ICS. Until recently, these medications were only available in separate inhalers.
At present, these medications are available in a single inhaler, like Seretide'n'
(fluticasone/salmeterol) and Symbicort@ (budesonide/formoterol). Combination
inhalers that combine long-acting B2-agonist with ICS may facilitate asthma
treatment by reducing the number of inhalations and inhalators and therefore have
the potential to improve the compliance and consequently asthma control. With the
availability of these new combination products, patients could be tempted to use
them in a situation of acute bronchoconstriction. In chapter 7, Symbicort'" reverses a
methacholine-induced bronchoconstriction rapidly, both objectively by means in
improvement in FEVI and subjectively by means of improvement in Borg score.
The fast onset of bronchodilatory effect was comparable with formoterol and
salbutamol in a similar model and even a lower dose of forrnoterol (6 pg) provided
a similar fast onset of action. From that study it remains unclear whether the
corticosteroid component of the combination contributed to the fast onset of effect.
The results suggest, however, that Symbicort'È has potential to be used as needed.
Long-acting B2-agonists are not only used in patients with asthma, but also in
patients with COPD. Many patients with COPD have cardior,'ascular comorbidity
and therefore are B-antagonists often needed. \il/hereas p2-agonists stimulate the
receptor, B-antagonists block the receptor. In the str"rdy described in chapter 8,
formoterol showed a rapid onset of action in reversing a methacholine-induced
bronchoconstriction in COPD-patients inevefsible to salbutamol, but its
effectiveness was hampered by B2-receptor blockade. This warrants the use of non-
selective B-adrenergic antagonists or higher doses of cardioselective B-adrenergic
antagonists. Remarkably, lipophilic B1-selective and non-selective antagonists were
found to deteriorate airway hyperresponsiveness in these patients with mild to
moderate COPD and irreversible airway obstruction. They may also have a negative
effect on lung function (FEVr). These results may have important bearings on the
management of COPD patients, especially since cardiovascular comorbidity is































































hold for patients with more severe COPD. In elderly patients with suspicion of
COPD, we recommend lung function measurements before B-antagonists are being
prescribed.
Conclusions
- rapid acting p2-agonists provide a rapid (objective and subjective) improvement
of dyspnoea.
formoterol shows also in vivo a higher intrinsic activity than salmeterol.
antagonistic properties of the partial agonist salmeterol do not readily occur in
vivo.
formoterol does not cause a stronger tolerance than salmeterol.
long-acting B-agonists do not deteriorate the perception of dyspnoea.
the combination of budesonide and formoterol in a single inhaler provides a
rapid, subjective and objective, improvement of dyspnoea.
in COPD, p-blockers may deteriorate airway hyperresponsiveness not only
because of B2-receptor blockade.
formoterol is effective in reversing a methacholine-induced bronchoconstriction
in patients with irreversible COPD, but its effectiveness can be compromised
by B2-receptor blockade.
the addition of long-acting B-agonists to inhaled corticosteroids improve the
compliance with inhaled corticosteroids.
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